Pennsylvania has enacted a significant shift in its approach to DUI enforcement, closing a long-standing loophole related to its Accelerated Rehabilitative Disposition (ARD) program. Previously, the state’s Supreme Court ruled
Pennsylvania has enacted a significant shift in its approach to DUI enforcement, closing a long-standing loophole related to its Accelerated Rehabilitative Disposition (ARD) program. Previously, the state’s Supreme Court ruled
Baker McKenzie represented Merit Medical Systems, Inc. (NASDAQ: MMSI), a global healthcare technology company, on its acquisition of View Point Medical, Inc., a privately held medical device company based in
Baker McKenzie is advising Genki Global Dining Concepts Corporation (GGDC) (TSE stock code: 9828) on its acquisition of Food Odyssey Pty. Ltd., operator of Australian sushi chain Sushi Sushi. This
On March 30, 2026, Herbert Smith Freehills Kramer client VICI Properties Inc. (NYSE: VICI) announced the CAD$200.6 million / USD$144.4 million pending acquisition of the real estate assets of Deerfoot
Utah is one of many states that maintains high prosecution rates, with over 396 per 100,000 residents being incarcerated, according to the Prison Policy Initiative. Being caught driving under the
Leading global law firm Herbert Smith Freehills Kramer has advised Meren Coöperatief U.A., a subsidiary of Meren Energy Inc. (Meren), on the refinancing of its reserve-based lending (RBL) facility. The
Workplace injuries can happen when you least expect them, leaving you overwhelmed and unsure of what steps to take next. Understanding how to file a workers’ compensation claim in North
Baker McKenzie has advised a consortium of investors led by Junction Growth Investors, Korys and BNP Paribas (via its Solar Impulse Venture Fund) in connection with the financing of flexibility
Linklaters is advising Encyclis, an EQT portfolio company, on the sale of its 50% ownership stake in Dublin Waste to Energy Limited to the Universities Superannuation Scheme, and is advising
Sidley represented Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, in its US$77 million Series